Multifcoal ERG in Hydroxychloroquine Retinopathy

1,759 views

Published on

Published in: Health & Medicine
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
1,759
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
50
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

Multifcoal ERG in Hydroxychloroquine Retinopathy

  1. 1. Multifocal ERG in Hydroxychloroquine RetinopathyMaria Noel Vacarezza, MDPeter J Savino, MDRaed Behbehani, MDElizabeth L Affel, MS
  2. 2. Hydroxychloroquine Retinal Toxicity Infrequent. Irreversible. Increased by: – High daily (6.5mg/kg/d)(cumulative(?)) dose. – Duration of treatment (>5yrs). – Renal/hepatic disease. – Obesity. – Age (>60). – Concurrent retinal disease.
  3. 3. Current Screening Recommendations (AAO) Complete ophthalmologic examination. Visual field: Humphrey 10-2 (white) Amsler grid. Color vision: Ishihara. Optional tests: – Fundus Photography. – IVFA. – Electrophysiologic studies (mfERG). Baseline and depending on risks thereafter
  4. 4. Guidelines for monitoring HCQ toxicity (Am C Rheumatology) No baseline evaluation if <40, no eye disease F/U: visual changes, fundus & visual fields 6-12m Warning symptoms (night vision, glare, reading difficulties)
  5. 5. mfERG early toxicity screening?
  6. 6.  6 symptomatic patients – 5 pts abnormal mfERG (1 had Humph 10-2) – Early screening device? So SC et al 2003 11 patients (10 asymptomatic/1 symptomatic) – 7 pts abnormal mfERG (normal AVF) – Preclinical toxicity? Penrose PJ et al 2004 15 patients – 7 pts abnormal mfERG (3 normal HVF 30/24-2)) – mfERG useful in identifying retinal cause when VF abnormal – may detect abnormalities earlier than other tests Maturi RK et al 2004
  7. 7. mfERG early toxicity screening? Inclusion criteria: – >5 years on hydroxychloroquine – >18 years old – Normal ophthalmologic exam – Normal VF (Humphrey 10-2 Red) – No history of retinal disease
  8. 8.  Complete ophthalmologic exam: – VA – Slit lamp – Tonometry – Color vision (Ishihara) – Fundus – Visual Field (Humphrey 10-2 Red) – Red Amsler mfERG
  9. 9. ResultsPt # Age/ Disease Yrs Daily Cum S&S HVF mfERG sex HCQ dose dose 10-2 1 F/60 RA 18 200 1,314g --- --- abnl 2 F/62 RA 11 400 1,606g --- --- abnl 3 F/57 ESL 15 400 2,190g --- --- abnl 4 F/46 ESL 10 2/400 1,250g --- --- abnl 5 F/52 RA 7 400 1,022g --- --- wnl 6 F/42 ESL 15 400 2,190g --- --- wnl 7 F/48 RA 13 400 1,898g --- --- wnl
  10. 10. Difference from normal OD OSPatient #2 Normal Patient #2 Normal
  11. 11. Patient #2OD OS Normal
  12. 12. CONCLUSION mfERG may be useful as the first indicator of developing macular toxicity even when the “standard” tests are normal. mfERG possibly should be added as an investigation in patients at higher risk to develop toxicity.
  13. 13. References Kellner U, Kraus H, Foerster MH. Multifocal ERG in chloroquine retinopathy: regional variance of retinal dysfunction. Graefe’s Arch Clin Exp Ophthalmol (2000) 238:94-97. Mavikakis I, Sfikakis PP, Mavikakis E, Rougas K, Nikolau A, Kostopoulos C, Mavikakis M. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine. Ophthalmology 2003, 110 (7):1321-26. So SC, Hedges TR, Schuman JS, Quireza MLA. Evaluation of Hydroxychloroquine Retinopathy With Multifocal Electroretinography. Ophthalmic Surgery, Lasers & Imaging. May/June 2003. Vol 34, No 3. Easterbrook M. Long-term course of Antimalarial Maculopathy after Cessation of Treatment. Can J Ophthalmol (1992) 27 (5): 237-9. Carr R, Henkind P, Rothfield N, Siegel I. Ocular Toxicity of Antimalarial Drugs, long term follow-up. Am J Ophthalmol (1968) 66: 738-44. Marmor M, Carr R, Easterbrook M, Farjo A, Mieler W. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy. A Report by the American Academy of Ophthalmology. Ophthalmol (2002) 109 (7): 1377-82. Penrose PJ, Tzekov R, Sutter EE, Fu AD, Allen AW, Fung WE, Oxford KW. Multifocal electroretinography evaluation for early detection of retinal dysfunction in patients taking hydroxychloroquine. Retina 2003, 23 (4):503-512.

×